More on GILD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $121.48 |
|
|||
| Open | $121.79 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $127.37 | ||||
| Day Low | $121.79 | ||||
| P/E | 69.54 | ||||
| EPS | $1.81 | ||||
| Volume | 8,665,602 | ||||
- Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Berger Dietmar
- Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Cain Wettan Keeley M
- Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Dickinson Andrew D
- Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: Mercier Johanna
- Form 4 GILEAD SCIENCES, INC. For: Jun 10 Filed by: O'Day Daniel Patrick
- National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
- Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald
- Gilead and Merck announce successful HIV treatment trial results
- Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
- Merck and Gilead discontinue lung cancer drug combination trial
Entities mentioned with GILD
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
